Tripla negatív emlőrák: ki dolgozik rajta

Intézményenként egy kártya. Válassz célpontot, és csak az azon dolgozó csoportok maradnak.

• Minden célpont
• PD-L1 26
• HER2 24
• PD-1 36
• BRCA1 5
• STAT3 1
• STING 0
• EGFR 4
• PI3K 1
• AKT 0
• BRCA2 2
• TP53 1
• PARP 1
• mTOR 0
• TROP2 6
• AR 1
• PTEN 0
• VEGF 4
• CDK4/6 3
• HIF-1 0
• MYC 0
• GPX4 0
• YAP 0
• CTNNB1 0
• JAK 1
• HDAC 0
• MAPK 0
• BCL-2 0
• CXCR4 1
• ERK 0
• NRF2 0
• PPAR 0
• B7-H3 4
• EZH2 0
• FAK 0
• PRMT5 0
• CD47 0
• HSP90 0
• PSMA 4
• IL-6 0
• PIK3CA 2
• CTLA-4 1
• HER3 2
• TNF 0
• COX-2 0
• IGF1R 0
• MEK 0
• FGFR 0
• MDM2 2
• MET 0
• MUC1 3
• NLRP3 0
• PALB2 0
• AMPK 0
• CD40 0
• CSF1R 1
• JNK 0
• METTL3 0
• MMP-9 0
• PKM2 0
• SIRT1 0

1+ intézményből 1, a friss publikációk és a nyitott vizsgálatok szerint rendezve. Ez nem minőségi rangsor.

Funded research projects that name this disease in their title, terms or summary and have not ended yet: who is funded, where, how much and until when. Organisations only; the funder's page has the details.

• European Commission (Horizon Europe) · HORIZON-TMA-MSCA-PF-EF

  DuoLipo-TNP: Dual-Responsive Liposome Platform for Selective Delivery of Triphosphate Nucleotide Prodrugs in Triple-Negative Breast Cancer

  Cardiff University· Cardiff, Egyesült Királyság· EU contribution 260 348 EUR· until 2029. ápr.· 2 countries

• European Commission (Horizon Europe) · HORIZON-TMA-MSCA-PF-EF

  Mapping antigenic niches of tumor-infiltrating B cells in triple-negative breast cancer (MAP-BC)

  Karolinska Institutet· Stockholm, Svédország· EU contribution 252 180 EUR· until 2028. dec.

• European Commission (Horizon Europe) · HORIZON-TMA-MSCA-SE

  Biomimetic MXene Nanoplatforms for Targeted Combination Therapy of Triple-Negative Breast Cancer (BioMIX)

  Latvijas Universitate· Riga, Lettország· EU contribution 1 147 740 EUR· until 2030. okt.· 12 countries

• European Commission (Horizon Europe) · HORIZON-EIC

  Next generation therapeutic vaccine for targeted cancer treatment (VacciNEXT)

  Basinnov Life Sciences Unipessoal Lda· Lisboa, Portugália· EU contribution 2 827 529 EUR· until 2029. szept.· 3 countries

• European Commission (Horizon Europe) · HORIZON-TMA-MSCA-PF-EF

  Co-culture System with Microfluidics and Onboard Sensors for Breast Cancer study (CoSMOS-BC)

  Universidad del Pais Vasco/ Euskal Herriko Unibertsitatea· Leioa, Spanyolország· EU contribution 209 915 EUR· until 2028. aug.

  The disease is named only in the funder's project summary, not in the title.

• European Commission (Horizon Europe) · HORIZON-TMA-MSCA-PF-EF

  Radiation-Induced Resistance in Triple-Negative Breast Cancer Organoids: Decoding the Role of Dose Fractionation and the Tumour Microenvironment in Precision Radiotherapy (RIoBORG)

  Centre National de la Recherche Scientifique Cnrs· Paris, Franciaország· EU contribution 226 421 EUR· until 2028. aug.

• European Commission (Horizon Europe) · HORIZON-ERC-POC

  AN OFF-THE-SHELF VACCINE FOR TRIPLE-NEGATIVE BREAST CANCER (TWISTAR)

  Vib Vzw· Zwijnaarde - Gent, Belgium· EU contribution 150 000 EUR· until 2028. febr.

• European Commission (Horizon Europe) · HORIZON-TMA-MSCA-PF-EF

  Identification of long non-coding RNA-based biomarkers of immunotherapy response in Triple-Negative Breast Cancer via liquid biopsy profiling (Triple-R)

  Fundacion Para la Investigacion de Malaga En Biomedicina y Salud· Malaga, Spanyolország· EU contribution 209 915 EUR· until 2028. júl.

• European Commission (Horizon Europe) · HORIZON-ERC-POC

  A Paradigm Shift in Systemic Cancer Radiotherapy: ‘Golden’ Nanoplatform for Pharmacokinetic Precision and Universal Metabolic Targeting (GOLDEN-RT)

  Bar Ilan University· Ramat Gan, Izrael· EU contribution 150 000 EUR· until 2027. dec.

  The disease is named only in the funder's project summary, not in the title.

• European Commission (Horizon Europe) · HORIZON-TMA-MSCA-PF-EF

  Harnessing natural killer cells to combat chemotherapy resistance (NatK)

  University of Bristol· Bristol, Egyesült Királyság· EU contribution 276 188 EUR· until 2028. ápr.

  The disease is named only in the funder's project summary, not in the title.

10 of 24 running projects, newest first. Listed amounts together: 18,5 M EUR.

Sources: NIH RePORTER (U.S. National Institutes of Health, public domain) and CORDIS (European Commission, CC BY 4.0). Changes: filtered by disease, organisations matched to ROR.

Leállított, visszavont és felfüggesztett vizsgálatok, a szponzor által a regiszterben megadott okkal, szó szerint idézve.

• Leállították

  NUV-868 as Monotherapy and in Combination With Olaparib or Enzalutamide in Adult Patients With Advanced Solid Tumors

  NCT05252390· Nuvation Bio Inc.· Frissítve: 2025. nov. 6.

  “The Sponsor has achieved its objectives.”A regiszter szövege, változtatás nélkül. Forrás

Vizsgálatok, amelyek regiszteradata szerint az egyéni résztvevői adatokat (IPD) megosztják.

• Radiation, Immunotherapy and PARP Inhibitor in Triple Negative Breast Cancer

  NCT04837209· Massachusetts General Hospital· Forrás

• Platinum and Polyadenosine 5'Diphosphoribose Polymerisation Inhibitor for Neoadjuvant Treatment of Triple Negative Breast Cancer and/or Germline BRCA Positive Breast Cancer

  NCT03150576· Cambridge University Hospitals NHS Foundation Trust· Forrás

Publikációk erről a betegségről egy MeSH-módszerkifejezés szerint, például szekvenálási vagy képalkotó módszerre.

• Single-Cell Analysis 46
• Organoids 9
• Mendelian Randomization Analysis 2
• CRISPR-Cas Systems 10
• Gene Expression Profiling 110
• Sequence Analysis, RNA 8
• Whole Genome Sequencing 4
• Exome Sequencing 5
• Proteomics 32
• Metabolomics 14
• Mass Spectrometry 3
• Flow Cytometry 11
• Immunohistochemistry 49
• Liquid Biopsy 4
• Circulating Tumor DNA 16
• Xenograft Model Antitumor Assays 254
• Positron-Emission Tomography 13
• Magnetic Resonance Imaging 34
• Machine Learning 28
• Deep Learning 15
• Cohort Studies 21
• Genome-Wide Association Study 3

• Luminal B-like predominance in breast cancer: A 5-year institutional experience of 2271 women from a tertiary cancer center in South India.

  J Cancer Res Ther, 2026. okt.

• HER2-low breast cancer: a new diagnostic challenge for pathologists - insights from a single-center retrospective cohort.

  Pol J Pathol, 2026. okt.

• Circulating Immune-Related Biomarkers in Egyptian Women with Early Breast Cancer: An Exploratory Case-Control Study Across IHC-Defined Clinicopathological Subgroups.

  Cells, 2026. okt.

• 1H HR-MAS NMR Metabolomics in Combination With Transcriptomic Correlation Provides New Insights Into Metabolic Heterogeneity Across Breast Cancer Immunohistochemical Subtypes.

  NMR Biomed, 2026. okt.

• Integrated collagen architecture and composition improve risk stratification in triple-negative breast cancer.

  Neoplasia, 2026. szept.

• Association of cancer antigen 15-3 with distant recurrence in immunohistochemically defined breast cancer subtypes in Canadian Cancer Trials Group MA.32.

  JNCI Cancer Spectr, 2026. szept.

• Immunohistochemical Characterization of the Androgen Receptor in Breast Cancer and Its Relationship with Breast Cancer Subtypes.

  Med Sci (Basel), 2026. aug.

• Immunohistochemistry-based molecular subtypes and stromal tumor-infiltrating lymphocytes in triple-negative breast cancer: a chemotherapy-only cohort.

  Oncologist, 2026. aug.

• Profiling Dectin-2-Positive Tumor-Associated Macrophages Across Human Cancers by Immunohistochemistry.

  Lab Invest, 2026. júl.

• A Robust Protocol for the Establishment, Expansion, Bio-Banking, and Molecular Profiling of Triple-Negative Breast Cancer Organoids.

  Appl Immunohistochem Mol Morphol, 2026. júl.

Megmutatjuk, a betegség mely célpontjait említi az absztrakt, és onnan a rajtuk dolgozókhoz jutsz.